

We Claim:

1. (Previously Cancelled)
2. (Previously Cancelled)
3. (Previously Amended) A compound selected from the group consisting of:

(1 α , 5 α , 6 α)-6N-[3-benzyl-3-azabicyclo[3.1.0]hexyl]-3-methyl-4-oxo- α -phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 1);

(1 α , 5 α , 6 α)-6N-[3-(4-cyanobenzyl)-3-azabicyclo[3.1.0]hexyl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 2);

(1 α ,5 α , 6 α)-N-[3-benzyl-3-azabicyclo [3.1.0] hexyl-6-(aminomethyl)-yl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 3);

(1 α ,5 α ,6 α)-N-[3-(4-methyl-3-pentyl)-3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 4); and

N-[3-benzyl-3-azabicyclo[3.1.0]hexyl-1-(aminomethyl)-yl]-3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide (Compound No. 5).
4. (Previously Amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as defined in claim 3 together with pharmaceutically acceptable carriers, excipients, or diluents.
5. (Currently Amended) A method for treatment of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is urinary incontinence, ~~lower urinary tract symptoms (LUTS)~~, bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes, and gastrointestinal hyperkinesia, comprising administering to said animal or human, a therapeutically effective amount of a compound of claim 3.

6. (Cancelled)

7.– 8. (Previously Cancelled).

9. (Currently Amended) The method for treatment of an animal or a human suffering from a disease or disorder of the respiratory, urinary, and gastrointestinal systems, wherein the disease or disorder is urinary incontinence, ~~lower urinary tract symptoms (LUTS)~~, bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes, and gastrointestinal hyperkinesis, comprising administering to said animal or human, a therapeutically effective amount of the pharmaceutical composition according to claim 4.

10. (Previously Cancelled).

11.– 18. (Previously Cancelled).